Sequelae of pelvic inflammatory disease Chronic pelvic pain
Conditions
Interventions
Sponsors
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: (1) It meets the diagnostic criteria of chronic pelvic pain in the sequelae of pelvic inflammatory diseases; (2) The average score of pain VAS in the week before inclusion >=4; (3) At the time of enrollment, the MC Cormack Scale scored 4-12 points (including 4 points and 12 points); (4) Female aged 18 to 55 years (including 18 and 55 years), who have a sexual life history; (5) Volunteered to participate in this clinical trial, informed consent and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Pelvic inflammatory disease (acute attack); (2) pregnant and lactating women who are unwilling to take effective measures to prevent pregnancy during the trial and within 3 months after the end of the trial; (3) Critical condition or indications of operation, such as complicated with diffuse peritonitis and sepsis; (4) Chronic pelvic pain caused by cervical intraepithelial neoplasia, primary/secondary dysmenorrhea, pelvic stasis syndrome and other non-pelvic inflammatory diseases have been clearly diagnosed in the past; (5) Specific vaginitis, such as vulvovaginal candidiasis, trichomoniasis vaginitis and bacterial vaginosis, were complicated at the time of enrollment; (6) Gynecological tumors (uterine fibroids with maximum diameter greater than 3cm and submucosal fibroids), endometriosis, myoadenosis, acute cervicitis, tuberculous pelvic inflammatory disease, interstitial cystitis and other diseases caused by related symptoms; (7) IUD was placed in the last 3 months; Absence of uterus and bilateral appendages; (8) Have received relevant treatment or taken drugs with similar functions within 14 days before introduction; (9) Liver function index (ALT, AST) >=1.5 ULN, and renal function index SCR >=1 ULN; (10) Serum CA125 and erythrocyte sedimentation rate >=1.5 ULN; (11) Routine blood indicators (RBC, WBC, HB, PLT) >=1.5 ULN; Fasting blood glucose exceeded the upper limit of the normal reference value; Twelve lead electrocardiogram showed abnormal QT interval (12) Complicated with serious cardiovascular, cerebrovascular, hematopoietic system and other serious diseases; (13) Have a history of allergy to test drug ingredients; (14) A history of long-term alcohol and drug abuse; (15) having intellectual or mental retardation; (16) Participated in other clinical trials within the last 3 months; (17)The investigator did not consider it appropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pregnancy test;liver function;Routine blood test;12-lead electrocardiogram;renal function;Urinary routine; | — |
Countries
China
Contacts
Public ContactTeng Xiuxiang
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Outcome results
None listed